Drug
Atirmociclib clinical trials
Also written PF-07220060.
- studies test it
- 14
- open now
- 4
- in phase 3
- 2
- first study started
- 2018
Keep track of what changes. Save the atirmociclib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
14 studies that test it; most in 2025 (5)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2022 | 1 |
| 2024 | 4 |
| 2025 | 5 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 5
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 0
Pfizer (11) · Olema Pharmaceuticals, Inc. (1) · Hoffmann-La Roche (1) · AstraZeneca (1)
Often tested with
Tested in the same studies.
Ribociclib (2) · Vepdegestrant (1) · Alpelisib (1) · Everolimus (1) · Itraconazole (1) · Probenecid (1) · Atezolizumab (1) · Ipatasertib (1)
Studies
Open first, then newest update. How each study uses atirmociclib is read from its arms, and is right about nine times in ten.
Testing it · 14
- A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast CancerNot yet recruitingPhase 3PfizerNCT07890597Written as Atirmociclib
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Written as Atirmociclib
- Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast CancerRecruitingPhase 2AstraZenecaNCT07427394Written as Atirmociclib
- A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver DiseaseRecruitingPhase 1PfizerNCT07677358Written as Atirmociclib
- Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic DiseaseActive, not recruitingPhase 3PfizerNCT06760637Written as PF-07220060
- A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.Active, not recruitingPhase 1/2PfizerNCT06206837Written as PF-07220060
- Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerActive, not recruitingPhase 1Olema Pharmaceuticals, Inc.NCT05508906Written as Atirmociclib
- Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy ParticipantsCompletedPhase 1PfizerNCT07215078Written as atirmociclib (PF-07220060)
- A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of TreatmentActive, not recruitingPhase 2PfizerNCT06105632Written as PF-07220060 CDK4 inhibitor
- A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post MenopauseCompletedPhase 2PfizerNCT06465368Written as PF-07220060
- A Study to Compare Two Tablet Formulations of Study Medicine Atirmociclib in Healthy ParticipantsCompletedPhase 1PfizerNCT07130097Written as PF-07220060
- A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060CompletedPhase 1PfizerNCT07160738Written as PF-07220060
- A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy AdultsCompletedPhase 1PfizerNCT06267963Written as Oral PF-07220060
- A Study to Learn if the Study Medicine Called Carbamazepine Changes How the Body Processes PF-07220060CompletedPhase 1PfizerNCT06897683Written as PF-07220060
Given in every arm · 4 — atirmociclib is usual care beside what is tested
- Study of PF-07248144 in Advanced or Metastatic Solid TumorsRecruitingPhase 2PfizerNCT04606446Written as PF-07220060
- Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsRecruitingPhase 1/2PfizerNCT04557449Written as PF-07220060
- First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast CancerRecruitingPhase 1Relay Therapeutics, Inc.NCT05216432Written as PF-07220060 100mg
- First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast CancerActive, not recruitingPhase 1OnKure, Inc.NCT06239467Written as Atirmociclib
Codes
What other systems call atirmociclib · ClinicalTrials.gg INT017864
- UNII (FDA) S743GOJ5LJATIRMOCICLIBConfirmed FDA, Wikidata
- Wikidata Q130633341atirmociclibConfirmed FDA, Wikidata
- NCI Thesaurus C175962AtirmociclibOne source FDA
- DrugBank DB21733One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | S743GOJ5LJ | ATIRMOCICLIB | Confirmed FDA, Wikidata |
| Wikidata | Q130633341 | atirmociclib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C175962 | Atirmociclib | One source FDA |
| DrugBank | DB21733 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.